WALTHAM, MA • 2022-06-03

BostonGene to Present at the 2022 American Society of Clinical Oncology Annual Meeting

5 min to read

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO)
WALTHAM, MA, June 3, 2022

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held June 3 – 7, 2022, at McCormick Place Convention Center in Chicago, IL.  BostonGene will also exhibit at booth 27087.

“We are excited to share our latest research at ASCO that underscores the critical need for innovative analytical tools to understand the composition and activity of the tumor and the microenvironment to improve treatment outcomes for cancer patients,” said Nathan Fowler MD, Chief Medical Officer at BostonGene.

Details about the abstracts selected for presentation can be found below:

Abstract Number: 4591
Title: A classification system for urothelial carcinoma (UC) defined by genomic drivers and the tumor microenvironment (TME) is predictive of immunotherapy response
Date and Time: Saturday, June 4 | 1:15 PM – 4:15 PM
Location: McCormick Place Convention Center, Hall A
Poster Number: 82
Speaker: Krystle Nomie, PhD, BostonGene

This presentation underscores the application of BostonGene’s transcriptome-based classification platform, previously reported by Bagaev et al., to identify TME subtypes for urothelial carcinoma that are predictive of response to immunotherapy.

Abstract Number: 3020
Title: A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity
Date and Time: Sunday, June 5 | 8:00 AM – 11:00 AM*
Location: McCormick Place Convention Center, Hall A
Poster Number: 12
Speaker: Zhongmin Xiang, PhD, BostonGene

*A follow-up poster discussion highlighting the AI-driven BostonGene MxIF analytical pipeline and its automated microenvironment characterization across cancers will take place from 4:30 PM – 6:00 PM in Hall D2

This presentation highlights the importance of innovative MxIF platforms to characterize tumor heterogeneity at single-cell resolution with high accuracy across many cancers.

Abstract Number: 3142
Title: A digital imaging analysis (DIA) platform for identifying tertiary lymphoid structures (TLS) in lung adenocarcinoma (LUAD)
Date and Time: Sunday, June 5 | 8:00 AM – 11:00 AM
Location: McCormick Place Convention Center, Hall A
Poster Number: 134
Speaker: Ekaterina Postovalova, PhD, BostonGene

This presentation demonstrates the ability of novel and cutting-edge imaging technologies in the BostonGene pipeline to detect tertiary lymphoid structures (TLS) in lung cancer.

Online publication abstract:

Abstract Number: e20624
Title: Longitudinal Molecular Analysis of Tumor Exome and Transcriptome to Evaluate Clonal Evolution and Identify Novel Therapeutic Targets in Thymoma

This abstract highlights the importance of a longitudinal comprehensive molecular analysis using genomic and transcriptomic sequencing to improve the understanding of rare thymic epithelial tumors.

Research conducted with Massachusetts General Hospital

For more information, please visit the 2022 ASCO Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings.

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin Keleher O'Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com